Biomarker-Driven Lung Cancer

Benjamin P. Levy, MD, discusses some of the ongoing trials exploring osimertinib in NSCLC and how the FLAURA data have impacted treatment decisions.

The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include&nbsp;the treatment of patients with metastatic non&ndash;small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br /> &nbsp;

Improving outcomes for disadvantaged patients with lung cancer has been a priority for over 5 years at Mary Bird Perkins-Our Lady of the Lake Cancer Center in Baton Rouge, Louisiana.

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.

H. Jack West, MD,&nbsp;thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses how he treats patients with advanced lung cancer who do not have actionable oncogenic drivers.&nbsp;

Multiple Myeloma

The FDA closed out the year by approving several new agents last month, including bevacizumab for glioblastoma, cabozantinib for renal cell carcinoma, nivolumab for melanoma, bosutinib for chronic myeloid leukemia, and pertuzumab for HER2+ breast cancer. In addition, several agents were granted a priority review designation. Here is a look back at all the FDA activity that took place in December.

Regardless of smoking history, patients with cancer of the lung harboring specific genetic alterations who were treated with targeted therapies experienced longer survival than those patients who did not receive targeted treatment, according to results of a multi-institutional extension study&nbsp;to identify and treat oncogenic driver events.

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.

A supplemental new drug application (sNDA) for osimertinib (Tagrisso) has been granted a priority review by the FDA&nbsp;as a first-line treatment for patients with non&ndash;small cell lung cancer (NSCLC) whose tumors harbor <em>EGFR</em> mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).

According to findings presented at the 2017 World Conference on Lung Cancer, the&nbsp;potent and selective inhibitor of ROS1 and TRKentrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with <em>ROS1</em> fusion-positive advanced non&ndash;small cell lung cancer.

AstraZeneca has submitted a&nbsp;supplemental new drug application to Japan&#39;s&nbsp;Pharmaceuticals and Medical Devices Agency for the use of the&nbsp;third-generation, irreversible EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) in the frontline treatment of patients with&nbsp;inoperable or recurrent <em>EGFR</em>-positive non&ndash;small cell lung cancer.

Suresh A. Ramalingam, MD,&nbsp;discusses some of the changes to the NCCN guidelines in NSCLC, specifically with <em>EGFR</em>-mutation&ndash;positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.

George R. Blumenschein, MD,&nbsp;discusses the current treatment landscape for patients with squamous cell lung cancer.

Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.

In data presented at the 2017 ESMO Asia Congress, updated results again sustained the benefit of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-positive advanced non&ndash;small cell lung cancer (NSCLC) and CNS metastases at baseline.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the future of treatment for oligometastatic lung cancer.

After granting a priority review to durvalumab (Imfinzi) in October for the treatment of patients&nbsp;with stage III, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation, the FDA is now reviewing results from the phase III PACIFIC trial, which have now&nbsp;been published in the print edition of the New England Journal Medicine.